Study author, publication year [reference] | Sample size (ASNQ/comparator) | Comparator drug | Study country | ASNQ group | Comparator group |
---|---|---|---|---|---|
Hombhanje et al., 2009 [19] | 51/49 | CQ-SP | PNG | Transient deafness: 7.8 % | Transient deafness: 2 % |
Itchiness: 2 % | Itchiness: 4 % | ||||
Skin rash: 2 % | Skin rash: 2 % | ||||
Dark urine: 2 % | Dark urine: 0 % | ||||
Vomiting: 2 % | Vomiting: 4.1 % | ||||
Rujumba et al., 2010 [20] | 113/112 | AL | Uganda | NA | NA |
Kinde-Gazard et al., 2012 [21] | 84/90 | AL | Benin | Nausea: 9.5 % | Nausea: 7.8 % |
Itchiness: 2.3 % | Itchiness: 2.2 % | ||||
Abdominal: pain: 6.3 % | Abdominal: pain: 5.5 % | ||||
Tjitra et al., 2012 [22] | 201/200 | DHP | Indonesia | Nausea: 57 % | Nausea: 54 % |
Headache: 55 % | Headache: 55 % | ||||
Udoh et al., 2014 [23] | 43/54 | AL | Nigeria | Transient maculopapular rash: 0.23 % | None |